Pre-IND, End-Of-Phase II Meetings Can Decrease Development Time, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency data indicate taking advantage of the early meetings with FDA officials can dramatically decrease mean clinical development times, especially for rare disease applications.